Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1075 of 1475 entries
View as:

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Phase: N/A Priority: Normal
NCT ID: NCT01003990 Org: User:
Start: 10/31/02 End: 02/29/16 Due: 02/28/17

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT03920267 Org: User:
Start: 03/26/19 End: 03/21/25 Due: 03/21/26

Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02717364 Org: User:
Start: 08/27/15 End: 03/07/18 Due: 03/07/19

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02726581 Org: User:
Start: 08/10/16 End: 03/09/22 Due: 03/09/23

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

Phase: N/A Priority: Normal
NCT ID: NCT03195491 Org: User:
Start: 12/25/17 End: 06/08/21 Due: 06/08/22

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01864174 Org: User:
Start: 06/20/13 End: 06/01/16 Due: 06/01/17

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Phase: N/A Priority: Normal
NCT ID: NCT00365339 Org: User:
Start: 04/30/06 End: 06/30/06 Due: 06/30/07

A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT00295282 Org: User:
Start: 01/31/06 End: 01/31/08 Due: 01/31/09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase: N/A Priority: Normal
NCT ID: NCT06101134 Org: User:
Start: 11/06/23 End: 08/31/27 Due: 08/31/28

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05372354 Org: User:
Start: 10/18/22 End: 10/12/26 Due: 10/12/27

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01057810 Org: User:
Start: 07/31/10 End: 07/31/15 Due: 07/31/16

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04036435 Org: User:
Start: 08/12/19 End: 07/26/26 Due: 07/26/27

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

Phase: N/A Priority: Normal
NCT ID: NCT03131973 Org: User:
Start: 05/13/17 End: 11/10/17 Due: 11/10/18

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00833482 Org: User:
Start: 09/30/09 End: 02/28/11 Due: 02/28/12

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

Phase: N/A Priority: Normal
NCT ID: NCT00162188 Org: User:
Start: 05/31/01 End: 12/31/10 Due: 12/31/11

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Phase: N/A Priority: Normal
NCT ID: NCT02320058 Org: User:
Start: 03/05/15 End: 09/08/20 Due: 09/08/21

Expanded Access for Apixaban

Phase: N/A Priority: Normal
NCT ID: NCT05187286 Org: User:
Start: - End: - Due: -

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Phase: N/A Priority: Normal
NCT ID: NCT01598090 Org: User:
Start: 06/14/12 End: 05/15/15 Due: 05/15/16

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05813717 Org: User:
Start: 04/10/23 End: 10/02/23 Due: 10/02/24

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02927769 Org: User:
Start: 03/28/17 End: 05/28/24 Due: 05/28/25

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Phase: N/A Priority: Normal
NCT ID: NCT03509896 Org: User:
Start: 11/30/17 End: 09/28/19 Due: 09/28/20

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Phase: N/A Priority: Normal
NCT ID: NCT03199846 Org: User:
Start: 10/25/16 End: 12/31/17 Due: 12/31/18

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Phase: N/A Priority: Normal
NCT ID: NCT03378310 Org: User:
Start: 12/21/17 End: 02/22/18 Due: 02/22/19

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Phase: N/A Priority: Normal
NCT ID: NCT00095238 Org: User:
Start: 06/30/02 End: 07/31/08 Due: 07/31/09

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06027437 Org: User:
Start: 09/05/23 End: 11/10/23 Due: 11/10/24